|Year : 2008 | Volume
| Issue : 2 | Page : 97-105
|Emergency treatment of a snake bite: Pearls from literature
Syed Moied Ahmed, Mohib Ahmed, Abu Nadeem, Jyotsna Mahajan, Adarash Choudhary, Jyotishka Pal
Department of Anesthesiology and Critical Care, JN Medical College, Aligarh Muslim University, India
Click here for correspondence address and email
| Abstract|| |
Snake bite is a well-known occupational hazard amongst farmers, plantation workers, and other outdoor workers and results in much morbidity and mortality throughout the world. This occupational hazard is no more an issue restricted to a particular part of the world; it has become a global issue. Accurate statistics of the incidence of snakebite and its morbidity and mortality throughout the world does not exist; however, it is certain to be higher than what is reported. This is because even today most of the victims initially approach traditional healers for treatment and many are not even registered in the hospital. Hence, registering such patients is an important goal if we are to have accurate statistics and reduce the morbidity and mortality due to snakebite. World Health Organization/South East Asian Region Organisation (WHO/SEARO) has published guidelines, specific for the South East Asian region, for the clinical management of snakebites. The same guidelines may be applied for managing snakebite patients in other parts of the world also, since no other professional body has come up with any other evidence-based guidelines. In this article we highlight the incidence and clinical features of different types of snakebite and the management guidelines as per the WHO/SEARO recommendation.
Keywords: Anti snake venom, global issue, snakebite
|How to cite this article:|
Ahmed SM, Ahmed M, Nadeem A, Mahajan J, Choudhary A, Pal J. Emergency treatment of a snake bite: Pearls from literature. J Emerg Trauma Shock 2008;1:97-105
|How to cite this URL:|
Ahmed SM, Ahmed M, Nadeem A, Mahajan J, Choudhary A, Pal J. Emergency treatment of a snake bite: Pearls from literature. J Emerg Trauma Shock [serial online] 2008 [cited 2017 Jul 21];1:97-105. Available from: http://www.onlinejets.org/text.asp?2008/1/2/97/43190
Venomous animals account for much morbidity and mortality. Worldwide, it is estimated that more than 5 million persons per year are bitten by snakes, out of which approximately 100,000 develop severe sequelae. , The actual figure may be much more since in India alone the mortality is suggested to be around 30,000.  Out of the available yearly statistics, the United States alone had 50,000 cases of bites, of which 7000 were by venomous snakes. Interestingly, of those 7,000 snakebite victims, 1,200 did not seek medical attention and yet they fully recovered. In all, there were 15 fatalities and thus the chance of survival is 499 out of 500. According to an epidemiological survey among 19,000 individuals living in 26 villages in Burdwan district (West Bengal), there was an annual incidence of snakebite of 0.16% and a mortality rate of 0.016% per year.  Maharashtra reports an incidence of 70 bites per 100,000 population and a mortality of 2.4 per 100,000 persons per year.  Indian states with high incidence of snakebites cases are Tamil Nadu, West Bengal, Maharashtra, Uttar Pradesh, and Kerala.  In Myanmar (Burma) Russell's vipers are responsible for 90% of cases. In 1991, there were 14,000 bites with 1,000 deaths and in 1997, 8,000 bites with 500 deaths. Under-reporting is estimated at 12%.  In Bangladesh, a survey of 10% of the country in 1988-1989 revealed 764 bites with 168 deaths over the 1-year period. Cobra bites (34% of all bites) had a case fatality of 40%. In Vietnam there are an estimated 30,000 bites per year. Among 430 rubber plantation workers bitten by Malayan pit vipers between 1993 and 1998, the case fatality was 22%, but only a minority had received antivenom treatment. Fishermen are still occasionally bitten by sea snakes but rarely reach hospitals alive. Pakistan has an estimated 20,000 snakebite deaths each year.
In Nepal there is an estimated 20,000 snakebites each year, with about 200 deaths in hospitals, mainly in the Terai region. One survey suggested as many as 1,000 deaths per year. Among 16 fatalities recorded at one rural clinic during a monsoon season, 15 had died on their way to seek medical care. 
| Epidemiology|| |
Snakes are distributed throughout most of the earth's surface with some exceptions such as the Arctic, Antarctic, and many small islands. Snakes are poikilothermic carnivorous reptiles that have evolved the venomous apparatus for the purpose of procurement of food.  To a large extent the manifestation of snakebite depends upon the species of snake, and therefore identification of the type of snake is important. At times the bite mark might not be visible (e.g., in the case of krait). The killed snake brought as evidence helps in identification of snake, in which case species-specific monovalent Anti snake venom (ASV) can be administered. The clinical manifestations of the patient may not correlate with the species of snake brought as evidence. It is therefore advantageous to know the appearance of the snake so as to recognize the species.
The three major families of venomous snakes are the Elapidae, the Viperidae, and the Hydrophidae.
Elapidae (cobra, king cobra, krait, and coral snake): These snakes have heads that are of about the same width as their necks. The head is covered with large scales but lack laureal shields. Their pupils are round and they are oviparous. These snakes have grooved fangs that are short, fixed, and covered by mucous membrane. They, therefore, cannot bite through clothes and usually deliver only a sublethal dose.
Viperidae (vipers): The head of a viper is triangular, wider than the neck, and has laureal shields. They have vertically elliptical pupils and are ovi-viviparous. Their fangs are long, movable, and canalized like hypodermic needles. They are further subdivided into pit viper and pitless viper subfamilies. The Crotalinae (pit vipers) have a special sense organ, the pit organ, to detect their warm-blooded prey. This is situated between the nostril and the eye. The rattlesnake belongs to the pit viper subfamily, while the Russell's viper and the saw-scaled viper belong to the pitless viper subfamily.
Hydrophidae (sea snake): Sea snakes are found in the vicinity of the seacoast. They have a small head and a flattened tail that helps them swim. Though venomous, they seldom bite.
In India, more than 200 species of snakes have been identified but only 52 are poisonous; the common krait (Bungarus caeruleus), Indian cobra (Naja naja), Russell's viper (Daboia russelii), and saw-scaled viper (Echis carinatus) are the most poisonous ("the big four"). , In the Indian setting, almost two-thirds of bites are attributed to saw-scaled vipers, about one-fourth to Russell's viper, and only a small proportion to cobras and kraits. ,
Host and environmental factors
Thorough statistical analysis of snakebite is difficult and the available data is not always complete because of the varied distribution (and because most bites occur in remote villages). Snakebite may be termed an occupational disease, as farmers, plantation workers, herdsmen, hunters, or workers on development sites are mostly affected.  Snakebites show a classical seasonal variation, being more common in summers and in the rainy season, when it is associated with agricultural activities.  The majority of snakes do not bite without provocation; most bites are inflicted when the snakes are inadvertently trodden upon. Males are bitten almost twice as often as females,  with the majority of the bites being on the lower extremities. ,, Fortunately, 50% of bites by venomous snakes are "dry bites" that result in negligible envenomation. The percentage of dry bites ranges from 10-80% for various poisonous snakes. 
| Snake Venom|| |
The normal function of snake venom is to immobilize the prey and to assist in digestion. The toxic component of snake venom can be classified into four broad categories: enzymes, polypeptides, glycoproteins, and compounds of low molecular weight.  They can also be classified as protein (90-95%) and nonprotein (5-10%) compounds.  [Table 1] provides the chemical composition of snake venom.
Toxic effects of snake venom
The toxic effect of snake venom results from both the protein and the nonprotein component. It is further complicated by the inflammatory response of the victim's body.
Phospholipase A2 is present in the venom of all families of poisonous snakes and is the enzyme that has been most widely studied. Phospholipase A2 inhibits electron transfer at cytochrome C level and renders mitochondrial-bound enzymes soluble. It damages red blood cells, leukocytes, platelets, skeletal muscle, vascular endothelium, peripheral nerve endings, and the myoneural junction. 
Hyaluronidase helps spread of venom through tissues, and proteolytic enzymes are responsible for the local edema, blistering, and necrosis. 
α- Neurotoxins bind to acetylcholine receptors at the motor end-plate, whereas β- neurotoxins first cause release of acetylcholine at the nerve endings at the myoneural junction and then damage the endings, preventing further release of transmitter. All this leads to a flaccid paralysis of the victim.
Polypeptides, being smaller molecules, are rapidly absorbed into the systemic circulation and cause systemic toxicity in vessel-rich organs (e.g., heart, lung, kidneys, etc.) as well as at pre- and postsynaptic membranes.
| Clinical Features Of Snakebite|| |
Some people who are bitten by snakes (or suspect or imagine that they have been bitten) may develop quite striking symptoms and signs, even when no venom has been injected. This results from an understandable fear of the consequences of a real venomous bite. Anxious people may hyperventilate so that they develop pins-and-needles sensation in the extremities, spasm of their hands and feet, and dizziness. Others may develop vasovagal shock after the bite or suspected bite, with faintness and collapse with profound slowing of the heart. Others may become highly agitated and irrational and may manifest a wide range of misleading symptoms. 
The clinical presentation of a snakebite victim varies with the age and size of the patient, the species of snake, the number and location of the bites, and the quantity and toxicity of the venom.
Morbidity and mortality depends on the age and size of victim (children receive larger envenomation relative to body size) as well as comorbid conditions (elderly patients succumb more easily to snake venom).  Other factors affecting severity and outcome are listed in [Table 2]. Factors not contributing to outcome are size of the snake and time of bite (day/night). 
Bites by krait, coral snake, and some cobras are associated with minimal local changes; however, bite by the Indian cobra (Naja naja) results in tender local swelling, blistering, and necrosis. Local necrosis causes a picture of "wet gangrene" with a characteristic putrid smell due to the direct cytolytic action of the venom. "Skip lesions" are typical findings. Systemic absorption occurs through venous channels and result in neurotoxic symptoms. Nausea, vomiting, malaise, prostration, and abdominal pain are the usual initial systemic symptoms. Paralysis is heralded by ptosis, followed by ophthalmoplegia. Paralysis of facial, palatal, tongue, and neck muscles follow. Respiratory failure, precipitated by upper airway obstruction and paralysis of intercostals and diaphragm, is the usual cause of death. ,
Viper bite is primarily vasculotoxic. It causes rapidly developing swelling of the bitten part. Local necrosis is mainly ischemic as thrombosis blocks the local blood vessels and causes a dry gangrene. Systemic absorption is slow; it occurs via the lymphatics and leads to lymphangitis. Hemostatic abnormalities are characteristic of viper bites and are the cause of the complications that lead to death. A persistent ooze from the bite mark and the site of the IV cannula is an indication of the altered clotting mechanism. Hemorrhage and increased capillary permeability leads to shock and pulmonary edema. Oliguria ensues, followed by loin pain due to renal ischemia. Renal failure is the common event before death. ,
Sea snake bite
The effects of a sea snake bite are both myotoxic and neurotoxic and result in clinical and pathological changes typical of segmental myopathic lesions in the skeletal muscles. Muscle pains may last for several months unless treated. Myoglobin and potassium released from damaged skeletal muscle can cause renal failure, while the hyperkalemia thus produced may lead to cardiac arrest. 
The average fatal dose, LD50, in mice and the average time to fatality of various snakes poison is given in [Table 3].
| Management of Snakebite|| |
WHO/SEARO has published guidelines, specific for the South East Asia region, for the clinical management of snakebites; these guidelines appeared in the supplementary issue of the South East Asian Journal of Tropical Medicine and Public Health. 
WHO/SEARO guidelines are universally followed. The following management is as per the WHO guidelines
The aim of first aid is to retard the systemic absorption of venom and prevent life-threatening complications by prompt transport to a medical facility. First aid can be performed by victim himself/herself or by any person who happens to be nearby. Traditionally, first aid included making local incisions or "tattooing" at the site of the bite, attempts at suctioning venom out of the wound, use of tight bands (tourniquets) around the limb, and/or local application of ice packs. None of the traditional remedies have any proven medical benefit. They should be discouraged as they do more harm than good and delay transport to a medical facility. Incision, suction, electric shocks, cryotherapy, or washing the wound are contraindicated as any interference with the wound introduces infection, increases bleeding from the site, and hastens absorption of the venom.
The current guidelines for first aid include the following:
- Reassure the victim (70% of all snakebites are by nonvenomous snakes and 50% of bites by venomous species are dry bites  )
- Immobilize the affected limb (by bandage or clothes to hold splint, but tight arterial compression is not recommended)
- Promptly transfer of victim to hospital
Pressure immobilization method (PIM) was developed by the Australian Venom Research Unit, University of Melbourne, Australia, for rapidly acting neurotoxic elapid snake venom. As per the PIM, immobilization and bandaging of the bitten part is similar to that done in the case of a sprained ankle. Studies have shown that it is seldom applied correctly  in simulated environments and, moreover, mobilizing the limb for more than 10 min nullifies the benefits of even the correctly applied bandage. 
In most instances, health care providers, general public, or community health workers are the first responders to come to the aid of the snakebite victim. If outcomes are to be improved, it is vital that they should all be made aware of the importance of immediate immobilization of the limb and transfer to the hospital at the earliest.
Emergency care department
When the patient reaches the emergency department, evaluation should begin with the assessment of the airway, breathing, circulatory status, and consciousness.
Urgent resuscitation will be needed in those in shock (cardiovascular toxicity), those with respiratory failure (neurotoxin), and in those who have had cardiac arrest (due to hypoxia, cardiac toxicity, or hyperkalemia from rhabdomyolysis).
Oxygen should be administered to every envenomed patient and a large-bore intravenous catheter should be inserted. A bolus of normal saline or Ringer's lactate should be given to all patients with suspected envenomation. The patient may then be administered specific treatment after a precise history has been taken and thorough physical examination done.
Attempts should be made to determine whether a venomous snake has actually bitten the patient and, if so, the severity of the bite [Table 4]. It is essential to establish that the victim has been bitten by a snake and not by some other animal; this can be cross-checked by looking for fang marks and signs of local envenomation. If the victim has brought the snake, identification of the species should be carried out carefully, since crotalids can envenomate even when dead. This is why bringing the killed snake into the ED should be discouraged. Questions should be asked to determine the time elapsed since the snakebite and a brief medical history should be obtained (e.g., date of last tetanus immunization, use of any medication, presence of any systemic disease, and history of allergy). 
During the initial evaluation, the bite site should be examined for signs of local envenomation (edema, petechiae, bullae, oozing from the wound, etc) and for the extent of swelling. The bite site and at least two other, more proximal, locations should be marked and the circumference of the bitten limb should be measured every 15 min thereafter, until the swelling is no longer progressing. The extremity should be placed in a well-padded splint for at least 24 h. Serial measurement of circumference helps in estimating spread of venom and effect of antivenom.  Lymph nodes draining the limb should be palpated and the presence of lymphangitic lines noted.
Distal pulses should be checked and monitored if there is presence of gross swelling. The presence of a pulse does not rule out compartment syndrome however, and compartment pressure should be measured directly if there is concern that a compartment syndrome is developing. The diagnosis is established if the compartment pressure, measured directly by inserting a 22G IV cannula and connecting it with manometer, is raised above 55 cm water/saline. Direct measurement is necessary before resorting to fasciotomy since compartment syndrome is rare in snakebite victims and fasciotomy done without correction of hemostatic abnormality may cause the patient to bleed to death. 
Clues for severe snake envenomation should be sought.  They consist of the following:
- Snake identified is a very venomous one
- Rapid early extension of local swelling from the site of the bite
- Early tender enlargement of local lymph nodes, indicating spread of venom in the lymphatic system
- Early systemic symptoms
- Early spontaneous systemic bleeding (especially bleeding from the gums)
- Passage of dark brown urine
| Laboratory Investigations|| |
Although lab tests are of little value in the diagnosis of snake envenomation, they are useful for prognosticating and for making decisions about specific interventions. 
(a) The 20-min whole blood clotting test (20 WBCT): The 20 WBCT is a simple bedside test of coagulopathy to diagnose viper envenomation and rule out elapid bite. It requires a new clean, dry test tube made up of simple glass that has not been washed with any detergent. A few milliliters of fresh venous blood is drawn and left undisturbed in the test tube for 20 min; the tube is then tilted gently. If the blood is still liquid after 20 min, it is evidence of coagulopathy and confirms that the patient has been bitten by a viper. Cobras or kraits do not cause antihemostatic symptoms. 
(b) Enzyme linked immunosorbent assay (ELISA): ELISA tests are now available to identify the species involved, based on antigens in the venom.  These tests, however, are expensive and not freely available and thus have limited value in diagnosis; at present, they find use mainly in epidemiological studies.
Other nonspecific tests include
- Hemogram: The hemogram may show transient elevation of hemoglobin level due to hemoconcentration (because of the increased capillary leak) or may show anemia (due to hemolysis, especially in viper bites). Presence of neutrophilic leucocytosis signifies systemic absorption of venom.  Thrombocytopenia may be a feature of viper envenomation.
- Serum creatinine: This is necessary to rule out renal failure after viper and sea snake bite.
- Serum amylase and creatinine phosphokinase (CPK): Elevated levels of these markers suggests muscle damage (caution for renal damage).
- Prothrombin time (PT) and activated partial thromboplastin time (aPTT): Prolongation may be present in viper bite.
- Fibrinogen and fibrin degradation products (FDPs): Low fibrinogen with elevated FDP is present when venom interferes with the clotting mechanism.
- Arterial blood gas and electrolyte determinations: These test are necessary for patients with systemic symptoms.
- Urine examination: Can reveal hematuria, proteinuria, hemoglobinuria, or myoglobinuria. (Arterial blood gases and urine examination should be repeated at frequent intervals during the acute phase to assess progressive systemic toxicity).
- Electrocardiogram (ECG): Nonspecific ECG changes such as bradycardia and atrioventricular block with ST-T changes may be seen. 
- Electroencephalogram (EEG): Recently, EEG changes have been noted in up to 96% of patients bitten by snakes. These changes start within hours of the bite but are not associated with any features of encephalopathy. Sixty-two percent showed grade I changes, 31% cases manifested grade II changes (moderate to severe abnormality), and the remaining 4% showed severe abnormality (grade III). These abnormal EEG patterns were seen mainly in the temporal lobes. 
The first blood drawn from the patient should be typed and cross-matched, as the effects of both venom and antivenom can interfere with later cross-matching.
| Specific Therapy|| |
Anti-snake venom (ASV) are immunoglobulins prepared by immunizing horses with the venom of poisonous snakes and subsequently extracting and purifying the horses' serum. They are the only effective antidote for snake venom. Antivenoms may be species specific (monovalent/monospecific) or may be effective against several species (polyvalent/polyspecific). Antibodies raised against the venom of one species may have cross-neutralizing activity against other venoms, usually that from closely related species. This is known as paraspecific activity. As per the recommendations of WHO, the most effective treatment for snakebite is the administration of monospecific ASV  ; however, this therapy is not always available to snakebite victims because of its high cost, frequent lack of availability, and the difficulty in correctly identifying the snake. 
WHO recommends that if an adequate cold chain is in place, antivenoms should be prepared in the liquid form, since this reduces production costs and avoids the potential adverse physicochemical alterations to the product sometimes brought about by lyophilization. On the other hand, if the integrity of the cold chain cannot be guaranteed, antivenoms should be lyophilized to maintain stability. 
Several antivenom preparations are available internationally. In India, polyvalent antivenom prepared by Central Research Institute, Kasauli (HP) is effective against the most common Indian species [Table 5]. Antivenom produced at the Haffkine Corporation, Parel (Mumbai) is effective against the venom of even more species. [Table 6] lists ASV producers in India, both in the public as well as the private sector.
ASV is supplied in dry powder form and has to be reconstituted by diluting in 10 ml of normal saline/D 5 W. Mixing is done by swirling and not by vigorous shaking.
Indications for ASV
The correct use of antivenom is essential and requires an informed evaluation of the patient. Not every poisonous snakebite merits its use. Antivenom treatment carries a risk of severe adverse reactions and in most countries it is costly and may be in limited supply. It should therefore be used only in patients in whom the benefits of antivenom treatment are considered to exceed the risks. Crotalidae polyvalent immune Fab (ovine) (CroFab; FabAV) has recently been approved for use in the United States. CroFab is a venom-specific Fab fragment of immunoglobulin G (IgG) that works by binding and neutralizing venom toxins, facilitating their redistribution away from target tissues and their elimination from the body. It has been demonstrated that these fragments are safe and effective, with a low incidence of sequelae; however, allergic reactions can occur when any animal protein derivatives are administered to human subjects. The overall incidence of immediate and delayed allergic reactions to this product appears so far to be lower than that reported with conventional whole-IgG antivenom.  Antivenom is indicated whenever there are signs of systemic envenomation or presence of severe local swelling. See [Table 7] for details.
Antivenom should be ideally administered within 4 h of the bite, but is effective even if given within 24 h. The dosage required varies with the degree of envenomation.
Dose of ASV
Despite widespread use of antivenom, there have been virtually no clinical trials to determine the ideal dose.  The dosage has remained a matter of much debate. The conventional dosing in our setup is based on the degree of envenomation [Table 8].
WHO/SEARO recommends the dose of antivenom to be the amount required to neutralize the average venom yield when captive snakes are milked of their venom.  Published research has indicated that the Russell's viper injects, on average, 63 mg (SD: ± 7 mg) of venom in the first bite. , As each vial of polyvalent ASV neutralizes 6 mg of Russell's viper venom, the initial dose should be 8-10 vials to ensure that the majority of the victims are covered by the initial dose; this will also help keep the cost of ASV down to acceptable levels.  As snakes inject the same amount of venom into children and adults, children should receive the same dose of antivenom as adults. 
Response to infusion of antivenom is marked by normalization of blood pressure.  Within 15-30 min bleeding stops, though coagulation disturbances may take up to 6 h to normalize. Neurotoxicity begins to improve within the first 30 min, but patients may require 24-48 h for full recovery. 
A repeat dose of ASV should be given when there is persistence of blood incoagulability even after 6 h or continued bleeding after 1-2 h of the initial dose. ASV should also be repeated when there are worsening neurotoxic or cardiovascular signs even after 1-2 h. 
ASV can be administered either by slow intravenous injection at a rate of 2 ml/min or by intravenous infusion (antivenom diluted in 5-10 ml per kilogram body weight of normal saline or D 5 W and infused over 1 h). Slow intravenous injection has the advantage that a doctor or nurse is present during the injection period when there is a risk of some early reaction to the ASV. All patients should be strictly observed for an hour for development of any anaphylactic reaction. Epinephrine should always be kept ready before administration of antivenom.
ASV should never be given locally at the site of the snakebite since it has not been shown to be effective and, moreover, this route of administration is associated with significant risks. For example, it is extremely painful and may increase intracompartmental pressure. Intramuscular injections are also not preferred since ASV is composed of large molecules (IgG or fragments) which are absorbed slowly via lymphatics, making the bioavailability by this route poor as compared to intravenous administration. Other disadvantages include pain on injection and risk of hematoma formation and sciatic nerve damage in patients with hemostatic abnormalities.  Intramuscular injections should only be given in settings where intravenous access cannot be obtained and/or the victim cannot be transported to a hospital immediately.
ASV sensitivity testing
ASV sensitivity testing is no longer recommended as a lack of response does not predict the large majority of early (anaphylactic) or late (serum sickness type) reactions.  Such testing could also presensitize the patient to the serum protein and, in addition, often delays treatment.
Approximately 20% patients treated with ASV develop either early or late reaction. 
Early anaphylactic reactions occurs within 10-180 min of start of therapy and is characterized by itching, urticaria, dry cough, nausea and vomiting, abdominal colic, diarrhea, tachycardia, and fever. Some patients may develop severe life-threatening anaphylaxis characterized by hypotension, bronchospasm, and angioedema.
Pyrogenic reactions usually develop 1-2 h after treatment. Symptoms include chills and rigors, fever, and hypotension. These reactions are caused by contamination of the ASV with pyrogens during the manufacturing process.
Late (serum sickness-type) reactions develop 1-12 (mean 7) days after treatment. Clinical features include fever, nausea, vomiting, diarrhea, itching, recurrent urticaria, arthralgia, myalgia, lymphadenopathy, immune complex nephritis and, rarely, encephalopathy.
Treatment of ASV reaction
When the patient shows signs of a reaction, antivenom administration must be temporarily stopped and adrenaline (1 in 1000) given intramuscularly in an initial dose of 0.5 mg in adults or 0.01 mg/kg body weight in children. The dose can be repeated every 5-10 min if necessary.
After adrenaline, an anti-H1 antihistamine such as chlorpheniramine maleate (adult dose 10 mg, children 0.2 mg/kg) should be given intravenously. It may be followed by intravenous hydrocortisone (adult dose 100 mg, children 2 mg/kg).
Late (serum sickness-type) reactions usually respond to a 5-day course of oral antihistamine (e.g., chlorpheniramine 2 mg six hourly in adults and 0.25 mg/kg/day in divided doses in children). Patients who fail to respond within 24-48 h should be given a 5-day course of prednisolone (5 mg six hourly in adults and 0.7 mg/kg/day in divided doses in children).
| Supportive Therapy|| |
The patient should be moved to an appropriate area of the hospital. The ICU will be required for patients with signs of severe envenomation (coma, respiratory paralysis, hypotension, pulmonary edema, and history of syncope). Patients with presence of fang marks, moderate pain, minimal local edema, erythema, ecchymosis, and no systemic reactions can be treated in the ward under close monitoring. Supportive therapy is required to buy time while the damaged organs recover. The types of supportive care that may be needed is summarized below.
Coagulopathy with bleeding
Coagulopathy usually reverses after ASV treatment. In exceptional cases, when there is severe bleeding or when urgent surgery is necessary, restoration of coagulability can be accelerated by giving fresh frozen plasma, cryoprecipitate (fibrinogen, factor VIII), fresh whole blood, or platelet concentrates. 
Antivenom treatment alone cannot be relied upon to save the life of a patient with bulbar and respiratory paralysis. Once there is loss of the gag reflex, failure to cough, or respiratory distress, endotracheal intubation and initiation of mechanical ventilation is indicated. Tracheostomy and placement of a cuffed tracheostomy tube can be done whenever expertise for endotracheal intubation is not available. Since Elapid toxin result in pathophysiological changes resembling those of myasthenia gravis, anticholinesterase drugs can have a useful effect in patients with neurotoxic envenomation, especially in those bitten by cobras. A trial of anticholinesterase should be performed in every patient with neurotoxic envenomation. Injection neostigmine can be given as 50-100 μg/kg 4 hourly or as a continuous infusion. Glycopyrrolate 0.2 mg can be given before neostigmine as, unlike atropine, glycopyrrolate does not cross the blood-brain barrier. Seneviratne and Dissanayake,  in a prospective study on the neurological manifestations, disease course, and outcome in neurotoxic envenomation, demonstrated that neostigmine improved the muscle weakness. However, the number of cases in the study was too small for them to make an unequivocal recommendation. They were of the opinion that it would perhaps be reasonable to offer anticholinesterase therapy to those who demonstrate a positive response to the tensilon test or a decremental response to repetitive nerve stimulation. 
Care of bitten part
The appearance of an immobile, tensely-swollen, cold, and apparently pulseless snake-bitten limb may suggest to surgeons the possibility of increased intracompartmental pressure, especially if the digital pulp spaces or the anterior tibial compartment are involved. Swelling of envenomed muscle within such tight fascial compartments could result in an increase in tissue pressure above the venous pressure and result in ischemia. However, the classical signs of an intracompartmental pressure syndrome may be difficult to assess in snakebite victims. Fasciotomy should not be contemplated until hemostatic abnormalities have been corrected, otherwise the patient may bleed to death. It has also been reported that fasciotomy worsens the amount of myonecrosis in crotalid snake venom-injected tissue. 
As most snakes harbor aerobic as well as anaerobic bacteria in their mouths, a prophylactic course of penicillin (or erythromycin for penicillin-hypersensitive patients) and a single dose of broad spectrum antibiotic course which will cover anaerobes together with a booster dose of tetanus toxoid is recommended. 
| Conclusion|| |
Snakes do not generally attack human beings unless provoked. However, once bitten, a wide spectrum of clinical manifestations may result. The emphasis should be on early and adequate medical management. Delayed medical management and lack of public awareness results in prolonged hospital and ICU stay of the patients. This can be decreased if regular public programmes regarding prevention, prehospital management (first aid), and the importance of early transfer to hospital are conducted.
Overemphasis on reducing the load of snake venom in the victim during prehospital management can be dangerous because its role is debatable and too much valuable time is wasted in its administration. Most of the traditional methods for first aid treatment of snakebite, both western and "traditional/herbal," have been found to result in more harm than good. Identification of the species of snake responsible for the bite is important for optimal clinical management. Antivenom is the only effective antidote for snake venom. However, it is expensive and usually in short supply and its use carries the risk of potentially dangerous reactions.
| References|| |
|1.||Swaroop S, Grab B. Snake bite mortality in the world. Bull WHO 1954;10:35-76. [PUBMED] |
|2.||Chippaux JP. Snake bites: Appraisal of the global situation. Bull WHO 1998;76:515-24. [PUBMED] |
|3.||Warrell DA. Injuries, envenoming, poisoning, and allergic reactions caused by animal. In: Warrell DA, Cox TN, Firth JD, Benz J Jr, editors. Oxford Textbook of Medicine. Oxford: Oxford University Press; 2003. p. 923-45. |
|4.||Hati AK, Mandal M, De MK, Mukherjee H, Hati RN. Epidemiology of snake bite in the district of Burdwan, West Bengal. J Indian Med Assoc 1992;90:145-7. [PUBMED] |
|5.||Gaitonde BB, Bhattacharya S. An epidemiological survey of snake-bite cases in India. Snake 1980;12:129-33. |
|6.||Philip E. Snake bite and scorpion sting. In: Srivatava RN editor. Pediatric and Neonatal Emergency Care. Jaypee Brothers; New Delhi: 1994. p. 227-34. |
|7.||Thein-Than. Development of renal function abnormalities following Russell's viper (Vipera russelli siamensis) bite in Myanmar. Trans Roy Soc Trop Med Hyg 1991;85:404-9. |
|8.||Bhetwal BB, O'Shea M, Warrell DA. Snakes and snake bite in Nepal. Trop Doctor 1998;28:193-5. |
|9.||Otten EJ. Venomous animal injuries. In: Rosen P, Barkin R, editors. Emergency Medicine concepts and clinical practices. New York: Mosby; 1998. p. 924-40. |
|10.||Parikh CK. Parikh's Textbook of Medical Jurisprudence, Forensic Medicine and Toxicology. 5th ed. New Delhi: CBS Publisher and Distributors; 1996 |
|11.||Simpson ID, Norris RL. Snakes of Medical Importance in India: Is the Concept of the "Big 4" Still Relevant and Useful? Wilderness Environ Med 2007;18:2-9. [PUBMED] |
|12.||Bhat RN. Viperine snake bite poisoning in Jammu. J Indian Med Assoc 1974;63:383-92. [PUBMED] |
|13.||Saini RK, Sharma S, Singh S, Pathania NS. Snake bite poisoning: A preliminary report. J Assoc Phys India 1984;32:195-7. |
|14.||Warrell DA. WHO/SEARO Guidelines for the clinical management of snakebite in the Southeast Asian Region. SE Asian J Trop Med Pub Hlth 1999;30:1-85. |
|15.||Seneviratne U, Dissanayake S. Neurological manifestations of snakebite in Sri Lanka. J Postgrad Med 2002;48:275-8. [PUBMED] |
|16.||Sharma N, Chauhan S, Faruqi S, Bhat P, Varma S. Snake envenomation in a north Indian hospital. Emerg Med J 2005;22:118-20. [PUBMED] [FULLTEXT]|
|17.||Kulakarni ML, Anees S. Snake venom Poisoning, experience with 633 patients. Indian Paediatr 1994;31:1239-43. |
|18.||Fernando P, Dias S. A case report: Indian krait bite poisoning. Ceylon Med J 1982;27:39-41. [PUBMED] |
|19.||Theakston RD, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003;41:541-57. [PUBMED] [FULLTEXT]|
|20.||Norris RL, Ngo J, Nohan K, Hooker G. Physicians and lay people are unable to apply pressure immobilisation properly in a simulated snakebite scenario. Wilderness Environ Med 2005;16:16-21. |
|21.||Howarth DM, Southee AS, Whytw IM. Lymphatic flow rates and first aid in simulated peripheral snake or spider envenomation. Med J Australia 1994;161:695-700. |
|22.||Hawgood BJ, Hugh AR. Investigation and treatment of snakebite. Toxicon 1998;36:431-46. |
|23.||Ho M, Warrell MJ, Warrell DA, Bidwell D, Voller A. A critical reappraisal of the use of enzyme-linked immunosorbent assays in the study of snakebite. Toxicon 1986;24:211-21. [PUBMED] [FULLTEXT]|
|24.||Reid HA. Animal Poisons. In: Manson Bahr PE, Apted FI, editors. Manson's Tropical Diseases, 18th ed. London: Balliere-Tindall; 1982. p. 544-6. |
|25.||Nayak KC, Jain AK, Sharda DP, Mishra SN. Profile of cardiac complications of snake bite. Indian Heart J 1990;42:185-8. [PUBMED] |
|26.||Ramachandran S, Ganaikabahu B, Pushparajan K, Wijesekara J. Electroencephalographic abnormalities in patients with snake bites. Am J Trop Med Hyg 1995;52:25-8. |
|27.||WHO. Regional Office for South-East Asia. Management of snake bites in South East Asia. The Clinical Management of Snake Bites in the Southeast Region Asia, 2005. Available from: http://www.searo.who.int/LinkFiles/SDE_mgmt_snake-bite.pdf [last accessed on 2007 Jul 12]. |
|28.||28.. Clark RF, McKinney PE, Chase PB, Walter FG. Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom. Ann Emerg Med 2002;39:671-6 |
|29.||Thomas PP, Jacob J. Randomised trial of antivenom in snake envenomation with prolonged clotting time. Br Med J 1985;291:177-8. |
|30.||Tun P, Khin AC. Amount of venom injected by Russells Viper (Vipera russelli). Toxicon 1986;24:730-3. |
|31.||Hazra A. Poisonous snake bites in India. Community Dev Med Unit Ration Drug Bull 2003;30:1-12. |
|32.||Simpson ID. Editorial: The Pediatric Management of Snakebite: The National Protocol. Indian J Paediatr 2007;44:173-6. |
|33.||Aung W, Tun T, Maung KM, Kyaw A, Pe H, Swe TN, et al. Clinical trial of intramuscular anti-snake venom administration as a first aid measure in the field in the management of Russell's viper bite patients. Southeast Asian J Trop Med Public Health 1996;27:494-7. |
|34.||Sawai Y. Study on deaths due to snakebite in Anuradhapura District, Sri Lanka. Snake 1984;16:7-15. |
|35.||Seneviratne U, Dissanayake S. Neurological manifestations of snake bite in Sri Lanka. J Postgrad Med 2002;48:275-8. [PUBMED] |
|36.||Tanen DA, Danish DC, Grice GA, Riffenburgh RH, Clark RF Fasciotomy worsens the amount of myonecrosis in a porcine model of crotaline envenomation. Ann Emerg Med 2004;44:99-104. |
|37.||Reddy KS. Essentials of forensic medicine and toxicology. 12th ed. Hyderabad: Laxmi Printers; 1980. |
|38.||Russell FE. Snake venom poisoning. 1st ed. Philadelphia: JB Lippincott Company; 1980. |
|39.||Reid HA, Thekaston RD. The management of snake bite. Bull WHO 1983;63:885-95. |
|40.||Snake Bites and Venom. Available from: http://www.thesnake.org. [last accessed 2007 Jul 3]. |
|41.||Chakraborty AK, Hall RH, Ghose AC. Purification and characterization of a potent hemolytic toxin with phospholipase A2 activity from the venom of Indian Russell's viper. Mol Cell Biochem 2002;237:95-102. [PUBMED] [FULLTEXT]|
|42.||Jena I, Sarangi A. Snakebite. In: Jena I, Sarangi A. Snakes of medical importance and snake-bite management. New Delhi: Ashish Publishing House; 1993. p. 99-105. |
|43.||Selvanayagam ZE, Neuzil P, Gopalkrishnakone P, Sridhar U, Singh M, Ho LC. An ISFET-based immunosensor for the detection of beta-bungarotoxin. Biosens Bioelectron 2002;17:821-6. |
Syed Moied Ahmed
Department of Anesthesiology and Critical Care, JN Medical College, Aligarh Muslim University
Source of Support: None, Conflict of Interest: None
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8]
|This article has been cited by|
||Cross neutralization of common Southeast Asian viperid venoms by a Thai polyvalent snake antivenom (Hemato Polyvalent Snake Antivenom)
| ||Poh Kuan Leong,Choo Hock Tan,Si Mui Sim,Shin Yee Fung,Khomvilai Sumana,Visith Sitprija,Nget Hong Tan |
| ||Acta Tropica. 2014; 132: 7 |
|[Pubmed] | [DOI]|
||Ophiophagus hannah Venom: Proteome, Components Bound by Naja kaouthia Antivenin and Neutralization by N. kaouthia Neurotoxin-Specific Human ScFv
| ||Witchuda Danpaiboon,Onrapak Reamtong,Nitat Sookrung,Watee Seesuay,Yuwaporn Sakolvaree,Jeeraphong Thanongsaksrikul,Fonthip Dong-din-on,Potjanee Srimanote,Kanyarat Thueng-in,Wanpen Chaicumpa |
| ||Toxins. 2014; 6(5): 1526 |
|[Pubmed] | [DOI]|
||The Snake Venom Rhodocytin from Calloselasma rhodostoma— A Clinically Important Toxin and a Useful Experimental Tool for Studies of C-Type Lectin-like Receptor 2 (CLEC-2)
| ||Řyvind Bruserud |
| ||Toxins. 2013; 5(4): 665 |
|[Pubmed] | [DOI]|
||Bedside Whole-Blood Clotting Times: Validity after Snakebites
| ||Damien Punguyire,Kenneth V. Iserson,Uwe Stolz,Stephen Apanga |
| ||The Journal of Emergency Medicine. 2013; 44(3): 663 |
|[Pubmed] | [DOI]|
||Treatment of a 41-year old female patient bitten by a viper conducted at the emergency department – A case report
| ||Rakesh Jalali,Aleksandra Winska-Tereszkiewicz,Krzysztof Nosek,Joanna Manta,Malgorzata Ciszewska,Bogdan Stusio,Andrzej Zawadzki,Dariusz Onichimowski |
| ||Polish Annals of Medicine. 2012; 19(1): 67 |
|[Pubmed] | [DOI]|
||Stenosing Flexor Tenosynovitis Following a Rattlesnake Bite
| ||Lydia Lee, Jeffrey Yao |
| ||Orthopedics. 2010; |
|[VIEW] | [DOI]|
||Coated cross-species antibodies by mannosamine–biotin adduct confer protection against snake venom without eliciting humoral immune response
| ||Tal Gefen, Jacob Pitcovski, Jacob Vaya, Soliman Khatib, Simi Krispel, E. Dan Heller, Elena Gaberman, Raphael Gorodetsky, Elina Aizenshtein |
| ||Vaccine. 2010; 28(51): 8197 |
|[VIEW] | [DOI]|
| Article Access Statistics|
| Viewed||14331 |
| Printed||335 |
| Emailed||15 |
| PDF Downloaded||573 |
| Comments ||[Add] |
| Cited by others ||7 |